GT
APLS

Glenmede Trust’s Apellis Pharmaceuticals APLS Stock Holding History

Glenmede Trust’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,157
Closed -$215K – 1282
2022
Q3 		$215K Buy
+3,157
New +$187K ﹤0.01% 1068
2020
Q4 		– Sell
-29
Closed – – 1257
2020
Q3 		$0 Hold
29
– – ﹤0.01% 2454
2020
Q2 		$0 Buy
+29
New +$931 ﹤0.01% 2437

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Glenmede Trust's APLS Position: Q4 2022 in Review

Glenmede Trust sold out of Apellis Pharmaceuticals (APLS) in Q4 2022, closing a stake of 3,157 shares — an estimated $215K sold.

Glenmede Trust first reported a position in APLS in Q2 2020 and held it in 3 quarters. The position peaked at $215K in Q3 2022. 244 funds tracked by Wall St. Rank hold APLS as of Q4 2022.

  • Glenmede Trust reported no remaining Apellis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Glenmede Trust sold 3,157 Apellis Pharmaceuticals shares in Q4 2022, an estimated $215K.
  • Glenmede Trust first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Glenmede Trust's Apellis Pharmaceuticals position peaked at $215K in Q3 2022.
  • 244 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2022.

Based on Glenmede Trust's 13F filing for Q4 2022, filed 14 Feb 2023.